| scholarly article | Q13442814 |
| P50 | author | Pengli Bu | Q56264143 |
| P2093 | author name string | Yue Zou | |
| Ales Vancura | |||
| Ivana Vancurova | |||
| Himavanth R Gatla | |||
| Mohammad M Uddin | |||
| Bipradeb Singha | |||
| P2860 | cites work | The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression | Q24548310 |
| Transcriptional regulation of chemokine expression in ovarian cancer | Q26825361 | ||
| Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. | Q28118359 | ||
| Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells | Q28142463 | ||
| Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation | Q28171193 | ||
| Cancer and the chemokine network | Q28269751 | ||
| Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug | Q28282479 | ||
| Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation | Q28302681 | ||
| The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta | Q29617188 | ||
| Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway | Q30310695 | ||
| Disruption of IkappaB kinase (IKK)-mediated RelA serine 536 phosphorylation sensitizes human multiple myeloma cells to histone deacetylase (HDAC) inhibitors | Q30424831 | ||
| Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death | Q30434141 | ||
| A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study | Q30445663 | ||
| Acetylation of p65 at lysine 314 is important for late NF-kappaB-dependent gene expression | Q33523177 | ||
| Histone deacetylase inhibitor therapy in epithelial ovarian cancer | Q33568495 | ||
| The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancer | Q33659166 | ||
| Murine CXCR1 is a functional receptor for GCP-2/CXCL6 and interleukin-8/CXCL8. | Q46976911 | ||
| Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy. | Q53563335 | ||
| Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. | Q53576275 | ||
| Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. | Q54033436 | ||
| Vorinostat | Q56002311 | ||
| Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells | Q73509785 | ||
| Upregulation of interleukin-8 and polarized epithelial expression of interleukin-8 receptor A in ovarian carcinomas | Q74330085 | ||
| HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells | Q80393092 | ||
| Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer | Q85484558 | ||
| Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation | Q33863049 | ||
| CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis | Q34095143 | ||
| Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer | Q34159472 | ||
| Histone deacetylases and cancer: causes and therapies | Q34570082 | ||
| Histone-deacetylase inhibitors: novel drugs for the treatment of cancer | Q34743301 | ||
| Nf-kappa B, chemokine gene transcription and tumour growth | Q34810265 | ||
| The interleukin-8 pathway in cancer. | Q34871322 | ||
| The IκB kinase complex in NF-κB regulation and beyond | Q35001723 | ||
| Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy | Q35109281 | ||
| Anticancer drug bortezomib increases interleukin-8 expression in human monocytes | Q35539175 | ||
| The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells | Q35556954 | ||
| IKK biology | Q35848596 | ||
| IKK inhibition increases bortezomib effectiveness in ovarian cancer | Q36413454 | ||
| Functional relevance of novel p300-mediated lysine 314 and 315 acetylation of RelA/p65 | Q36509262 | ||
| The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma | Q36544635 | ||
| The murine interleukin 8 type B receptor homologue and its ligands. Expression and biological characterization | Q36727002 | ||
| The murine homologue of the human interleukin-8 receptor type B maps near the Ity-Lsh-Bcg disease resistance locus | Q36760569 | ||
| Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications | Q37038216 | ||
| Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies | Q37226511 | ||
| Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth | Q37405207 | ||
| Proteasome inhibition increases recruitment of IκB kinase β (IKKβ), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells | Q37536497 | ||
| The NF-kappaB family of transcription factors and its regulation | Q37672294 | ||
| Chemokines and chemokine receptors: new insights into cancer-related inflammation. | Q37694068 | ||
| Posttranslational modifications of NF-kappaB: another layer of regulation for NF-kappaB signaling pathway | Q37723806 | ||
| The evolution of mammalian chemokine genes. | Q37740571 | ||
| NF-κB and chromatin: ten years on the path from basic mechanisms to candidate drugs | Q37995685 | ||
| Rationale and Means to Target Pro-Inflammatory Interleukin-8 (CXCL8) Signaling in Cancer. | Q38166232 | ||
| Interleukin-8 expression is regulated by histone deacetylases through the nuclear factor-kappaB pathway in breast cancer. | Q38288748 | ||
| Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells | Q38909786 | ||
| Activation of AMP-activated Protein Kinase by Metformin Induces Protein Acetylation in Prostate and Ovarian Cancer Cells | Q39297835 | ||
| Histone deacetylase inhibitors and aspirin interact synergistically to induce cell death in ovarian cancer cells. | Q39968749 | ||
| Regulatory effect of e2, IL-6 and IL-8 on the growth of epithelial ovarian cancer cells. | Q40337992 | ||
| Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action | Q40349894 | ||
| Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad. | Q40435886 | ||
| Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models | Q40577628 | ||
| Interleukin 8: an autocrine growth factor for human ovarian cancer. | Q40835312 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 5043-5054 | |
| P577 | publication date | 2017-02-06 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Histone Deacetylase (HDAC) Inhibition Induces IκB Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells | |
| P478 | volume | 292 |
| Q49887757 | Combination Therapies Targeting HDAC and IKK in Solid Tumors |
| Q64120382 | Effects of ginsenoside Rg3 on epigenetic modification in ovarian cancer cells |
| Q55418713 | Endometriosis Malignant Transformation: Epigenetics as a Probable Mechanism in Ovarian Tumorigenesis. |
| Q42378478 | Epigenetic regulation of interleukin-8 expression by class I HDAC and CBP in ovarian cancer cells |
| Q90397112 | Flavonoids and Other Polyphenols Act as Epigenetic Modifiers in Breast Cancer |
| Q91187764 | HDAC inhibitors promote intestinal epithelial regeneration via autocrine TGFβ1 signalling in inflammation |
| Q42338747 | HDAC/IKK inhibition therapies in solid tumors |
| Q64914861 | Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy. |
| Q64063293 | Regulation of Chemokines and Cytokines by Histone Deacetylases and an Update on Histone Decetylase Inhibitors in Human Diseases |
| Q52372117 | Targeting IκappaB kinases for cancer therapy. |
| Q57022016 | The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells |
| Q64075945 | Thymoquinone-Induced Reactivation of Tumor Suppressor Genes in Cancer Cells Involves Epigenetic Mechanisms |
| Q93077995 | Wnt/β-Catenin Signaling: The Culprit in Pancreatic Carcinogenesis and Therapeutic Resistance |
Search more.